Global Nasal Antiseptics Market By Based on Type (Interferons, Povidone- Iodine, Lactoferrin, Alcohols, Others), By Based on Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2022-2032

Nasal Antiseptics Market Introduction

An antiseptic is a liquid solution that kills germs. Nasal antiseptics are usually administered through the nasal cavity before surgery to help prevent infection. Nasal antiseptics are helpful for drug delivery and for treating nasal allergies. Allergies such as hay fever are common condition that causes symptoms such as sneezing, runny and stuffy nose, watery eyes, as well as the itching of the nose, eyes, or the roof of the mouth. According to data published in 2018 by the Asthma and Allergy Foundation of America (AAFA), allergic rhinitis affects 5.2 million children and 19.2 million adults.

A nasal antiseptic is available in many different forms, such as a liquid, spray, ointment, cream, swab, aerosol powder, and even soap. Many antiseptics are allotted for a particular infection such as SARS-COV2 virus, and COVID-19, which are inactivated with the help of PVP-I nasal antiseptic, and according to ongoing research & development activities, other antiseptics are also available in this market for the treatment of COVID-19. For instance, a study published by the journal Infectious Diseases and Therapy says the use of a Povidone-Iodine (PVP-I) nasal antiseptic solution to fight SARS-CoV-2, the virus that causes COVID-19.2.

Detailed Segmentation:

The global nasal antiseptics market is segmented on the basis of – Type, Distribution Channel, and Region.

Based on Type

• Lactoperoxidase
• Lactoferrin
• Interferons
• Povidone- Iodine
• Alcohols
• Others

Based on Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Based on Regions

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Market Dynamics

The growing prevalence of infections/allergies, booming geriatric populations, and increasing levels of pollution are some factors driving the economic growth of the global nasal antiseptic market. In addition, certain advantages offered by nasal antiseptics such as efficient and painless drug delivery, convenience, easy availability, etc., are also elements expected to boost revenue growth prospects for the nasal antiseptic market. In addition, the increasing number of surgical procedures is also likely to fuel the demand for antiseptic products, which, in turn, is expected to boost economic growth prospects for the global nasal antiseptic market over the forecast period.

The impact of the coronavirus (COVID-19) pandemic is expected to augment the revenue growth of the global nasal antiseptic market over the forecast period, owing to the surging number of COVID-19 cases, as well as rapid research in the development of diagnostics for COVID-19 patients during this pandemic. According to an article published by Healthline Media in June 2021, there are more than 70,000 new COVID-19 cases every week in the US.

Favorable government initiatives and funding may support research & development activities, which in turn may further complement the nasal antiseptics market. In 2019, the FDA approved Spravato (esketamine) nasal spray, taken with an oral antidepressant, to treat depressive symptoms in adults.

Whereas, adverse reactions due to nasal antiseptics such as nasal dryness, nasal dizziness, nasal congestion, etc., are restraining the market growth of the global nasal antiseptic industry. In addition, stringent regulations are also hindering the nasal antiseptics industry. Various instances of product recall reported by the FDA or companies themselves may act as a restraining factor for target market growth over the forecast period.

Key Players:

• Siemens Healthineers
• Hoffmann-La Roche Ltd.
• Mindray Medical International Limited
• Sysmex Corp.
• Abbott Laboratories
• Horiba Ltd.
• Danaher Corp.
• EKF Diagnostics Holdings Plc
• OmegaQuant LLC
• Sysmex Corporation
• Other Key Players

Key Developments

In 2020, a clinical-stage biopharmaceutical company, “BlueWillow Biologics Inc.,” announced the launch of NanoBio® Protect (NanoBio®), the first alcohol-free, moisturizing, long-lasting, Over-The-Counter (OTC) nasal antiseptic proven to kill 99.99% of infection-causing germs on contact.